GLP-1 maintenance phase: what the science says vs. TikTok

What's this video probably claiming?

Based on the caption and hashtag cluster, this creator is likely sharing personal experience transitioning from active weight loss on a GLP-1 medication (almost certainly tirzepatide, given the #tirzejourney and #tirzepatidecompound tags) into a maintenance phase. That typically means a stabilized dose, slower weight changes, and a shift in focus toward sustaining results rather than hitting new lows on the scale. The #wskincareroutine tag is interesting, and probably signals the creator is also talking about managing GLP-1-adjacent side effects on skin or body composition during maintenance. Videos in this genre often frame maintenance as a lifestyle identity rather than a medical protocol, which is where the clinical picture and the content start to diverge. The #tirzepatidecompound tag is a flag worth noting: this suggests the creator may be using a compounded version of tirzepatide, which carries its own distinct regulatory and safety considerations.

What does the science actually show?

The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) is the most relevant data we have on tirzepatide maintenance. Participants who continued tirzepatide after 36 weeks of active treatment maintained an average of 5.5% additional weight loss, while those who switched to placebo regained about 14% of their body weight over the following 52 weeks. That gap is striking and it makes one thing clear: maintenance on a GLP-1 is not passive. The drug is doing real, ongoing physiological work suppressing appetite via GIP and GLP-1 receptor pathways. What the science does not support is the idea that maintenance is simply a lifestyle adjustment achievable through skincare routines and hashtag communities. The underlying biology, including reduced resting energy expenditure following significant weight loss (Leibel et al., 1995, NEJM), persists whether you feel like you are in maintenance mode or not.

Where does the social media noise diverge from clinical reality?

The framing of GLP-1 maintenance as a "whole new ballgame" is emotionally resonant but clinically imprecise. TikTok content in this space tends to treat dose stabilization as an endpoint rather than a continuation of pharmacotherapy. A few patterns worth calling out:

• Compounded tirzepatide is not equivalent to Zepbound or Mounjaro. The FDA has stated that compounded versions are not FDA-approved and may differ in formulation, concentration, and sterility standards.
• Skin changes during GLP-1 use are real, but attributing them to a specific product routine versus rapid fat loss (which changes skin laxity and texture independently) is not something the current literature supports.
• The idea that maintenance requires less medical oversight is contradicted by SURMOUNT-4 data showing that discontinuation leads to rapid regain, meaning this is an ongoing clinical relationship, not a graduation event.

The lifestyle framing also tends to minimize that weight regain risk is highest in the first six months after dose reduction or discontinuation.

What should you actually know?

If you are on tirzepatide and approaching what feels like a maintenance phase, a few things are worth anchoring to. First, your prescriber should be leading that conversation, not a TikTok comment section. Dose adjustments in maintenance are individual and depend on tolerability, metabolic response, and goals that change over time. Second, the compounded tirzepatide market is actively being scrutinized. The FDA removed tirzepatide from its drug shortage list in late 2024, which has direct implications for the legal status of compounded versions going forward. Third, body composition changes during GLP-1 maintenance, including muscle mass considerations, are an area where the evidence is still developing. Resistance training and adequate protein intake appear to help preserve lean mass (Lundgren et al., 2023, Nature Medicine), but no skincare or supplement routine substitutes for that foundation. Maintenance is a medical phase, not a personality type.